Abstract
The actin cytoskeleton supports diverse cellular processes such as endocytosis, oriented growth, adhesion and migration1. The dynamic nature of the cytoskeleton, however, has made it difficult to define the roles of the many accessory molecules that modulate actin organization, especially the multifunctional adapter protein annexin II (refs. 2,3). We now report that the compound withaferin A (1) can alter cytoskeletal architecture in a previously unknown manner by covalently binding annexin II and stimulating its basal F-actin cross-linking activity. Drug-mediated disruption of F-actin organization is dependent on annexin II expression by cells and markedly limits their migratory and invasive capabilities at subcytotoxic concentrations. Given the extensive ethnobotanical history of withaferin-containing plant preparations in the treatment of cancer and inflammatory and neurological disorders, we suggest that annexin II represents a feasible, previously unexploited target for therapeutic intervention by small-molecule drugs4.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gardel, M.L. et al. Elastic behavior of cross-linked and bundled actin networks. Science 304, 1301–1305 (2004).
Revenu, C., Athman, R., Robine, S. & Louvard, D. The co-workers of actin filaments: from cell structures to signals. Nat. Rev. Mol. Cell Biol. 5, 635–646 (2004).
Hayes, M.J., Rescher, U., Gerke, V. & Moss, S.E. Annexin-actin interactions. Traffic 5, 571–576 (2004).
Mishra, L., Singh, B. & Dagenais, S. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha). Altern. Med. Rev. 5, 334–346 (2000).
Budhiraja, R.D., Krishan, P. & Sudhir, S. Biological activity of withanolides. J. Sci. Ind. Res. (India) 59, 904–911 (2000).
Waisman, D.M. Annexin II tetramer: structure and function. Mol. Cell. Biochem. 149–150, 301–322 (1995).
Ayala-Sanmartin, J., Gouache, P. & Henry, J.P. N-Terminal domain of annexin 2 regulates Ca(2+)-dependent membrane aggregation by the core domain: a site directed mutagenesis study. Biochemistry 39, 15190–15198 (2000).
MacLeod, T.J., Kwon, M., Filipenko, N.R. & Waisman, D.M. Phospholipid-associated annexin A2–S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J. Biol. Chem. 278, 25577–25584 (2003).
Filipenko, N.R. & Waisman, D.M. The C terminus of annexin II mediates binding to F-actin. J. Biol. Chem. 276, 5310–5315 (2001).
Caplan, J.F., Filipenko, N.R., Fitzpatrick, S.L. & Waisman, D.M. Regulation of annexin A2 by reversible glutathionylation. J. Biol. Chem. 279, 7740–7750 (2004).
Hofmann, A. et al. Interactions of benzodiazepine derivatives with annexins. J. Biol. Chem. 273, 2885–2894 (1998).
Burger, A. et al. The crystal structure and ion channel activity of human annexin II, a peripheral membrane protein. J. Mol. Biol. 257, 839–847 (1996).
Singh, T.K. & Liu, L. Modification of cysteine residues by N-ethylmaleimide inhibits annexin II tetramer mediated liposome aggregation. Arch. Biochem. Biophys. 381, 235–240 (2000).
Jones, P.G., Moore, G.J. & Waisman, D.M. A nonapeptide to the putative F-actin binding site of annexin-II tetramer inhibits its calcium-dependent activation of actin filament bundling. J. Biol. Chem. 267, 13993–13997 (1992).
Zobiack, N., Gerke, V. & Rescher, U. Complex formation and submembranous localization of annexin 2 and S100A10 in live HepG2 cells. FEBS Lett. 500, 137–140 (2001).
Puisieux, A., Ji, J. & Ozturk, M. Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms. Biochem. J. 313, 51–55 (1996).
Mai, J., Finley, R.L., Jr, Waisman, D.M. & Sloane, B.F. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J. Biol. Chem. 275, 12806–12812 (2000).
Kwon, M. et al. Identification of annexin II heterotetramer as a plasmin reductase. J. Biol. Chem. 277, 10903–10911 (2002).
Menell, J.S. et al. Annexin II and bleeding in acute promyelocytic leukemia. N. Engl. J. Med. 340, 994–1004 (1999).
Ishii, H. et al. Potential role of recombinant annexin II in diabetic vascular injury. Ann. NY Acad. Sci. 947, 308–311 (2001).
Oliferenko, S. et al. Analysis of CD44-containing lipid rafts: Recruitment of annexin II and stabilization by the actin cytoskeleton. J. Cell Biol. 146, 843–854 (1999).
Shevchenko, A., Wilm, M., Vorm, O. & Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850–858 (1996).
Yates, J.R., III, Eng, J.K., McCormack, A.L. & Schieltz, D. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal. Chem. 67, 1426–1436 (1995).
Acknowledgements
We thank V. Gerke and J. Ayala-Sanmartin for their gifts of recombinant annexin II and p11 expression plasmids; D.M. Waisman for human recombinant AIIt; G. Tsaprailis and C. Payne for suggestions; and the University of Arizona Electron Microscopy Core; the SWEHSC Proteomics Core and C. McLellan for technical assistance. The assistance of K. Wijeratne in obtaining physical and spectral data for biotinylated withaferin A is also appreciated. This work was supported by US National Institutes of Health (NIH) grants R21-CA091056 (L.W.) and R01-CA090265 (A.A.L.G.). Fellowship support was provided to R.F. by the Tee Up for Tots Foundation. Support for the Southwest Environmental Health Sciences Center was provided by National Institute of Environmental Health Sciences grant ES06694 and NIH/National Cancer Institute grant CA023074-26.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Effect of withaferin (WA) on cell morphology and survival. (PDF 2456 kb)
Supplementary Fig. 2
Design and synthesis of biotinyl-withaferin (B-WA) for solid phase immobilization. (PDF 582 kb)
Supplementary Fig. 3
Identification of annexin II (AII) as a target of withaferin (WA). (PDF 469 kb)
Supplementary Fig. 4
Withaferin (WA) binds to AIIt but not other annexin family members. (PDF 2241 kb)
Supplementary Fig. 5
5 Mass spectroscopy identification of withaferin (WA) adduct site in annexin II (AII). (PDF 467 kb)
Supplementary Fig. 6
Enforced expression of AIIt in HepG2 cells. (PDF 496 kb)
Rights and permissions
About this article
Cite this article
Falsey, R., Marron, M., Gunaherath, G. et al. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2, 33–38 (2006). https://doi.org/10.1038/nchembio755
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio755
This article is cited by
-
Affinity purification in target identification: the specificity challenge
Archives of Pharmacal Research (2015)
-
JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress
Cell Death & Disease (2014)
-
4β-Hydroxywithanolide E isolated from Physalis pruinosa calyx decreases inflammatory responses by inhibiting the NF-κB signaling in diabetic mouse adipose tissue
International Journal of Obesity (2014)
-
Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells
Investigational New Drugs (2014)
-
Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract
Cancer Immunology, Immunotherapy (2013)